atorvastatin has been researched along with Chlamydia pneumoniae Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dechend, R; Dietz, R; Gieffers, J; Joerres, A; Luft, FC; Maass, M; Rupp, J | 1 |
| Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH | 1 |
2 other study(ies) available for atorvastatin and Chlamydia pneumoniae Infections
| Article | Year |
|---|---|
Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Communication; Cell Membrane; Cells, Cultured; Chemokines; Chlamydophila Infections; Chlamydophila pneumoniae; Coculture Techniques; Dose-Response Relationship, Drug; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NF-kappa B; Protein Prenylation; Pyridines; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction | 2003 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2002 |